Setara Closes 90 Million Dollar Series A
Setara Biosciences announced on 30 October that it completed a $90 million Series A after Jazz acquired Actio’s lead KCNT1 epilepsy asset. Setara retains the remaining genetics-led pipeline, led by the TRPV4 inhibitor STAR-0871….
